about
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease.High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsRole of early PET in the management of diffuse large B-cell lymphoma.PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies.Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice.Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies.Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales.Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14Invasive pneumococcal disease in central Australia.Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.Evaluating the place of 18-fluoro-2-deoxy-D-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma.Rapidly fatal post-allogeneic stem cell transplant lymphoproliferative disorder presenting with skin and bone marrow involvement.Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience.Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström Macroglobulinemia.Prognostic model for high tumor burden follicular lymphoma integrating baseline and end induction PET: a LYSA/FIL study.Time to publish: challenging the performance of cooperative group lymphoma trials.Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Rising cost of anticancer drugs in Australia.Reply to G. Keramida et al.Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trialReply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et alHaemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydrationSubacute cardiac toxicity following autologous haematopoietic stem cell transplantation in patients with normal cardiac functionPharmacokinetics of melphalan in myeloma patients undergoing an autograftPositron emission tomography-computed tomography in follicular lymphoma: "one fit for all"?Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and SafetyReply to H.J.A. Adams et al and E. Laffon et alDoes end-of-treatment FDG-PET improve outcomes in follicular lymphoma? - Authors' replyRandomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell LymphomaFront-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma
P50
Q33437577-BC4403ED-C263-48B5-9F49-8A7B9EB9BE1BQ33795058-ABFB1D03-C64C-499F-9D70-246292BB8345Q35625473-CE00A4DD-737B-4E50-909F-05BFD2C157B7Q37030719-D418D3CD-D223-4484-B6D1-4E208325F771Q37126978-7EB1D5AB-5EEC-444A-9C81-435B2C09E4CCQ37240835-E9C75EF3-61FB-4656-8983-2E761D1DFA54Q37509428-E6B4801B-FF62-497F-8B61-5FCA8B5ACD8CQ37777595-17BBEEB2-8AEE-4458-80BA-369E6FFC341BQ38179303-C1F0F674-6C04-49BA-9973-AA323AE4FAF6Q38794103-74956A7C-3026-4F68-9130-40FC64EB4F66Q38983705-7D3A7107-A8BB-4B9D-AE38-E713C7F9EF22Q39464165-837D6F68-F6CF-4315-A7B5-EB799B031DD1Q40107848-D4C797DB-20B6-4610-900D-DA6085ADF819Q40332965-2D94D850-320E-49A2-85F2-38A8F2B6AEF0Q40356629-6D7C7E5B-78A0-430E-9F0A-EAF1D5322DCDQ40405986-877F311A-595A-4FAF-93CB-669E6F30E9F5Q40576636-B7DDB124-7D8E-415E-8A29-24113BB603A7Q43792807-660BD28A-E93A-49DE-BAEF-2951626CE368Q45927078-5575F75C-A10F-4614-9752-F272BDB622CBQ47567315-9B906832-D9FE-4595-970C-80BA7E378B9BQ47788410-802C8E60-F24E-44B2-93BD-F2ABE822477FQ48887999-F49D45B3-2B39-4344-B350-C48B7269CDD2Q50035097-4E21CB52-D038-4F5C-9EDB-3E1B1A66381FQ50827292-35F825BD-B9FB-411C-B22E-0880E72DBB77Q51028804-DDE01F1E-E47E-44A4-867D-FFA590151900Q51199274-DFD929C0-1FF8-4538-A4F0-6F7B9F6D9CDCQ51241237-1DDB6698-362C-4AC0-82C6-8C63FFF4679CQ52991409-766BD126-A9D1-4907-8D8B-372379054854Q54977551-93A5BE18-49EF-4320-8938-5B9D0123EFD0Q57481825-E4817840-07F0-422D-8039-85762D6234EBQ57758744-C8FE8A21-32B6-4226-8723-5E5452585C45Q77409062-B1DDEDCA-78D5-449F-BA3E-50AE462FB4FCQ80175197-AC6C0B54-F493-4C5C-B4A8-0E102021B8FAQ80751150-9201BA69-6D8E-45FB-A8EE-29D3966A5842Q86017389-81ACDF4F-641F-4A68-AC0C-AB979B11C324Q88949004-E944833F-3746-48AB-95E5-D418CCE05105Q89373340-59631835-EE8D-41C5-B725-DAF88036F78CQ90916353-2F814EE3-6598-4E0A-9002-8DE1D84221E6Q91304792-B65AE84D-D2B1-4E4F-8043-7F6DB23B9D14Q91534212-A6846727-9ADD-4146-935D-2190D0F215AF
P50
description
researcher
@en
name
J Trotman
@en
J Trotman
@nl
type
label
J Trotman
@en
J Trotman
@nl
prefLabel
J Trotman
@en
J Trotman
@nl
P106
P31
P496
0000-0001-8009-4593